The use of modeling in the economic evaluation of vaccines

References

• Trueman P, Drummond NW, Hutton J. Developing guidance for budget impact analysis. PharmacoEconomics 19 (6), 609–621 (2001).
   PubMed Web of Science ®Google Scholar
• Drummond ME, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of healthcair programmes, second edition. Oxford Medical Publications, Oxford, UK (1997).
   Google Scholar
• Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat. Med. 18, 3262–3282 (1999).
   Google Scholar
• ••Excellent background article on thedifferences between static and transmission dynamic models.
   Google Scholar
• Clemens J, Brenner R, Rao M, Tafari N, Lowe C. Evaluating new vaccines for developing countries. Efficacy or effectiveness? /AIWA 275, 390–397 (1996).
   Google Scholar
• Anderson RM, May RM. Infectious diseases of humans; chnamics and control. Oxford University Press, New York, NY, USA (1991).
   Google Scholar
• ••Textbook on the dynamics of infectiousdiseases.
   Google Scholar
• Beutels P, Edmunds WJ, Antonanzas F et al Economic evaluation of vaccination programmes; a consensus statement focusing on viral hepatitis. PharmacoEconomics 20, 1–7(2002).
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med. Decis. Making13, 322–338 (1993).
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M. In introduction to Markov modelling for economic evaluation. PharmacoEconomics 13(4), 397–409 (1998).
   PubMed Web of Science ®Google Scholar
• •Excellent introduction into Markov modelling.
   Google Scholar
• Beutels P, Bonanni P, Tormans G, Canale F, Crovari PC. An economic evaluation of universal pertussis vaccination in Italy. Vaccine 17(19), 2400–2409 (1999).
   Google Scholar
• Holtgrave DR (Ed.) Handbook of economic evaluation of HIV prevention programs. Plenum Press, New York, NY, USA (1998).
   Google Scholar
• Pinkerton SD, Abrahamson PPR. Evaluating the risks: A Bernoulli proces model for HIV infection and risk reduction. Evaluation Rev 17,504–528 (1993).
   Web of Science ®Google Scholar
• Bos JM, Fennema JS, Postma MJ. Cost- effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam. AIDS15, 2031–2036 (2001).
   Google Scholar
• Postma MJ, Welte R, van der Hoek JAR, van Doomum GJJ, Jager JC, Coutinho RA. Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia trachomatis Value in I-kalth 4,266–275 (2001).
   Google Scholar
• Rahman M, Sekimoto M, Takamatsu I etal. Economic evaluation of universal BCG vaccination of Japanese infants. Int. j Epidemiol 2,380–385 (2001).
   Google Scholar
• Pathania VS, Trnka L, Krejbich F, Dye C. A cost-benefit analysis of BCG revaccination in the Czech Republic. Vaccine 17(15-16), 1926–1935 (1999).
   Google Scholar
• Williams JR, Nokes DJ, Medley GF, Anderson RM. The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluation costs and effectiveness of immunisation programmes. Epidemiol Inf. 116(1), 71–89 (1996).
   Google Scholar
• •Example of the use of transmission dynamic models in cost-effectiveness analysis.
   Google Scholar
• Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JA/V/A 276(14), 172–177 (1996).
   Google Scholar
• Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JA/V/A 276(15), 1253–1258 (1996).
   Google Scholar
• Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAIVIA 276(16), 1339–1341 (1996).
   PubMed Web of Science ®Google Scholar
• Gold M. Panel on cost-effectiveness in health and medicine. Merl Care 34(12 Suppl.), D5197-199 (1996).
   Google Scholar
• Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am. Gastroenterol 97(2), 427–434 (2002).
   Google Scholar
• Arnal JM, Frisas 0, Garuz R, Antonanzas Cost effectiveness of hepatitis A virus immunisation in Spain. PharmacoEconomics 12(3), 361–373 (1997).
   Google Scholar
• Buma AH, Beutels P, van Damme P, Tormans G, van Doorslaer E, Leentvaar-Kuijpers A. An economic evaluation of hepatitis A vaccination in Dutch military personnel. MI Med 163(8), 564–567 (1998).
   Google Scholar
• Fenn P, McGuire A, Gray A. An economic evaluation of vaccination against hepatitis A for frequent Travellers. j Infect. 36(1), 17–22 (1998).
   Google Scholar
• Diel R, Rappenhohner B, Schneider S. Cost effectiveness of hepatitis A immunisation of children and adolescents in Germany. HEPA C2,96–103 (2001).
   Google Scholar
• O'Connor JB, Imperiale TF, Singer ME. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults. Hepatology 4,1077–1081 (1999).
   Google Scholar
• Rajan E, Shattock AG, Fielding JF. Cost- effective analysis of hepatitis A prevention in Ireland. Am. J. Gastroenterol 95(1), 223–226 (2000).
   Google Scholar
• Meltzer MI, Shapiro CN, Mast EE, Arcari C. The economics of vaccinating restaurant workers against hepatitis A. Vaccine 19(15-16), 2138–2145 (2001).
   Google Scholar
• Gillis D, Yetiv N, Gdalevich M et al Active versus passive immunization against hepatitis A in the Israel defence forces: a cost-benefit analysis. Vaccine 18(26), 3005–3010 (2000).
   PubMed Web of Science ®Google Scholar
• Jacobs RJ, Grover SF, Meyerhoff AS, Paivana TA. Cost effectiveness of vaccinating food service workers against hepatitis A infection. j Food Prot. 63(6), 768–774 (2000).
   Google Scholar
• Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Hepatology 31 (4), 834–839 (2000) .
   PubMed Web of Science ®Google Scholar
• Jacobs RJ, Margolis HS, Coleman PJ. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch. Pediah: Adolesc. Merl 154(8), 763–770 (2000).
   Google Scholar
• Saab S, Martin P, Yee HF Jr. A simple cost- decision analysis model comparing two strategies for hepatitis A vaccination. Am j Merl 109(3), 241–244 (2000).
   Google Scholar
• Ginsber GM, Slater PE, Shouval D. Cost- benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J. Hepatol 34(1), 92–99 (2001).
   Google Scholar
• Smith S, Weber S, Wiblin T, Nettleman M. Cost-effectiveness of hepatitis A vaccination in healthcare workers. Infect. Control Hosp. Epidemiol 18(10), 688–691 (1997).
   Google Scholar
• Chodick G, Lerman Y, Peled T, Aloni H, Ashkenazi S. Cost-benefit analysis of active vaccination campaigns against hepatitis A among daycare centre personnel in Israel. PhatmacoEconomics 19(3), 281–291 (2001).
   PubMed Web of Science ®Google Scholar
• Chodick G, Lerman Y, Wood F, Aloni H, Peled T, Ashkenazi S. Cost-utility analysis of hepatitis A prevention among healthcare workers in Israel. j Occup. Environ. Merl 44(2), 109–115 (2002).
   Google Scholar
• Szucs T Cost-effectiveness of hepatitis A and B vaccination programme in Germany. Vaccine 18(Suppl. 1), S86–89 (2000).
   Google Scholar
• Wiewiora-Pilecka D. Cost-benefit analysis of the Polish hepatitis B prevention programme. Vaccine 18\(Suppl. 1), S52-54 (2000).
   Google Scholar
• Krahn M, Guasparini R, Sherman M, Detsky AS. Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am. j Public Health. 88(11), 1638–1644 (1998).
   PubMed Web of Science ®Google Scholar
• Fenn P, Gray A, McGuire A. An economic evaluation of universal vaccination against hepatitis B virus. j Infect. 32(3), 197–204 (1996).
   Google Scholar
• Garuz R, Torrea JL, Arnal JM et al Vaccination against hepatitis B virus in Spain: a cost-effectiveness analysis. Vaccine 15(15), 1652–1660 (1997).
   PubMed Web of Science ®Google Scholar
• Williams JR, Nokes DJ, Anderson RM. Targeted hepatitis B vaccination: a cost-effective immunisation strategy for the UK? Epidemiol Community Health 50,667–673 (1996).
   Google Scholar
• Fabrizi F, Di Filippo S, Marcelli D et al Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. Nephron 72(4), 536–543 (1996).
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli E Intradermal versusim. hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial. 7iansplant. 12(6), 1204–1211 (1997).
   Google Scholar
• Miller MA, Kane M. Routine hepatitis B immunisation in India: cost-effectiveness assessment. Indianj Perliatt: 67(4), 299–300 (2000).
   Google Scholar
• Taal MW, van Zyl-Smit R. Cost- effectiveness of hepatitis B vaccination in haemodialysis patients. S. All: Merl j 91(4), 340–344 (2001).
   Google Scholar
• Levaux HP, Schonfeld WH, Pellissier JM, Cassidy WM, Sheriff SK, Fitzsimon C. Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents. Pediatrics 108(2), 317–325 (2001).
   Google Scholar
• Da Villa G, Sepe A. Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. Vaccine 17(13-14), 1734–1738 (1999).
   Google Scholar
• Harris A, Yong K, Kermode M. An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib—HepB): a decision analytic approach to cost effectiveness. Aust. NZJ Public Health. 25(3), 222–229 (2001).
   Google Scholar
• Fendrick AM, Lee JH, LaBarge C, Glick HA. Clinical and economic impact of a combination Haemophilus intluenzae and Hepatitis B vaccine: estimating cost-effectiveness using decision analysis. Atch. Perliatc Adolesc Merl 153(2), 126–136 (1999).
   PubMedGoogle Scholar
• Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 20(9-10), 1316–1330 (2002).
   PubMed Web of Science ®Google Scholar
• Tormans G, Van Doorslaer E, van Damme P, Clara R, Schmitt HJ. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany. Eur. I Pediab: 157 (5), 395–401 (1998).
   Google Scholar
• Iskedjian M, Einarson TR, O'Brien BJ et al Economic evaluation of a new acellular vaccine for pertussis in Canada. PhalmacoEconomics19(5 Pt 2), 551–563 (2001).
   Google Scholar
• Barnato AE, Sanders GD, Owens DK. Cost-effectiveness of a potential vaccine for Coccidioides immitis Emerg. Infect. Dis. 7(5), 797–806 (2001).
   Google Scholar
• Bos JM, Rumke HC, Welte R, Postma MJ, Jager JC. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. Vaccine 20 (1-2), 202–207 (2001).
   Google Scholar
• Skull S, Butler J. Meningococcal vaccination for adolescents? An economic evaluation in Victoria. J. Paerliab: Child Health 37(5), 28–33 (2001).
   Google Scholar
• Skull SA, Butler JR, Robinson P, Carnie J. Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation. int. I Epidemiol. 30(3), 571–578 (2001).
   Google Scholar
• Parent du Chatelet I, Gessner BD, da Silva A. Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis. Vaccine 19(25-26), 3420–3431 (2001).
   Google Scholar
• Bos JM, Postma MJ. The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa. PhalmacoEconomic519(9), 937–946 (2001).
   Google Scholar
• Sisk JE, Moskowitz AJ, Whang Wet al Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. PIMA 278(16), 1333–1339 (1997).
   Google Scholar
• Postma MJ, Heijnen ML, Jager JC. Cost- effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. PharmacoEconomics 19(2), 215–222 (2001).
   PubMed Web of Science ®Google Scholar
• Baltussen RMPM, Ament AJHA, Leidl RM, van Furth R. Cost-effectiveness of vaccination against pneumococcal pneumonia in the Netherlands. Eur Public Health 7,153–161 (1997).
   Google Scholar
• Ament A, Baltussen R, Duru G et al Cost- effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin. Infect. Dis. 31(2), 444–450 (2000).
   Google Scholar
• De Graeve D, Lombaert G, Goossens H. Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium. PharmacoEconomics 17(6), 591–601 (2000).
   PubMed Web of Science ®Google Scholar
• Weycker D, Richardson E, Oster G. Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs. Am. J. Manag. Cate 6(10 Suppl.), S526-535 (2000).
   Google Scholar
• Black S, Lieu TA, Ray GT, Capra A, Shinefield HR. Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente. Vaccine 19\(Suppl. 1), S83-86 (2000).
   Google Scholar
• Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman IF, Miller MA, Shinefield HR. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAIVIA 283(11), 1460–1468 (2000).
   PubMed Web of Science ®Google Scholar
• Vold Pepper P, Owens DK. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. Clin. Infect. Dis. 30(1), 157–164 (2000).
   Google Scholar
• Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch. Intern. Merl 159(20), 2437–2442 (1999).
   Google Scholar
• Hueston WJ, Mainous AG 3rd, Brauer N. Predicting cost-benefits before programs are started: looking at conjugate vaccine for invasive pneumococcal infections. J. Community Health 25(1), 23–33 (2000).
   Google Scholar
• Marra CA, Patrick DM, Marra E A cost- effectiveness analysis of pneumococcal vaccination in street-involved, HIV-infected patients. Can. J. Public Health 91(5), 334–339 (2000).
   Google Scholar
• Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children. J. Infect. Dis. 174\(Suppl. 3), S335-341 (1996).
   Google Scholar
• Tennenberg AM, Brassard JE, Van Lieu J, Drusin LM. Varicella vaccination for healthcare workers at a university hospital: an analysis of costs and benefits. Infect. Control Hasp. Epidemiol. 18(6), 405–411 (1997) .
   Google Scholar
• Smith WJ, Jackson LA, Watts DH, Koepsell TD. Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet. Cynecol 92(4 Pt 1), 535–545 (1998).
   Google Scholar
• Brisson M, Edmunds WJ. The cost- effectiveness of varicella vaccination in Canada. Vaccine 20,1113–1115 (2002).
   PubMed Web of Science ®Google Scholar
• Nettleman MD, Schmid M. Controlling varicella in the healthcare setting: the cost effectiveness of using varicella vaccine in healthcare workers. Infect. Control Hasp. Epidemiol. 18(7), 504–508 (1997).
   Google Scholar
• Burnham BR, Wells TS, Riddle JR. A cost- benefit analysis of a routine varicella vaccination program for United States Air Force Academy cadets. MI Med. 163(9), 631–634 (1998).
   Google Scholar
• Gayman J. A cost-effectiveness model for analyzing two varicella vaccination strategies. Ainj Health Syst. Pharm. 55(24 Suppl. 4), 4–8 (1998).
   Google Scholar
• Gray AM, Fenn P, Weinberg J, Miller E, McGuire A. An economic analysis of varicella vaccination for healthcare workers. Epidemiol Infect. 119(2), 209–220 (1997).
   Google Scholar
• Coudeville L, Paree F, Lebrun T, Sailly J. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine17(2), 142–151 (1999).
   Google Scholar
• Howell MR, Lee T, Gaydos CA, Nang RN. The cost-effectiveness of varicella screening and vaccination in US Army recruts. Med. 165,309–315 (2000).
   Google Scholar
• Diez Domingo J, Ridao M, Latour J, Ballester A, Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 17(11-12), 1306–1311 (1999).
   Google Scholar
• Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 18(5-6), 407–415 (1999).
   PubMed Web of Science ®Google Scholar
• Smith KJ, Roberts MS. Cost effectiveness of vaccination strategies in adults without a history of chickenpox. Am. J. Med. 108(9), 723–729 (2000).
   Google Scholar
• Olson AD, Shope TC, Flynn JT. Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation. Pecliab: Transplant. 5(1), 44–50 (2001).
   Google Scholar
• Scuffham P, Devlin N, Eberhart-Phillips J, Wilson-Salt R. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Soc. Sci Med. 49(6), 763–779 (1999).
   Google Scholar
• Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin. Infect. Dis. 33(11), 1879–1885 (2001).
   Google Scholar
• Luce BR, Zangwill KM, Palmer CS et al Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 108(2), E24 (2001).
   Google Scholar
• Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJ. Economic evaluation of influenza vaccination. Assessment for The Netherlands. PharmacoEconomics16\(Suppl. 1), 33–40 (1999).
   Google Scholar
• Dayan GH, Nguyen VH, Debbag R, Gomez R, Wood SC. Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vaccine 19(30), 4204–4213 (2001).
   Google Scholar
• Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch. Intern. Med. 161(5), 749–759 (2001).
   Google Scholar
• Burckel E, Ashraf T, de Sousa Filho JP eta]. Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company. PharmacoEconomics 16(5 Pt 2), 563–576 (1999).
   Google Scholar
• Fitzner KA, Shortridge KF, McGhee SM, Hedley AJ. Cost-effectiveness study on influenza prevention in Hong Kong. Health Polig,56(3), 215–234 (2001).
   Google Scholar
• Wood SC, Alexseiv A, Nguyen VH. Effectiveness and economical impact of vaccination against influenza among a working population in Moscow. Vaccine 17\(Suppl. 3), S81-87 (1999).
   Google Scholar
• Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 106(5), 973–976 (2000).
   Google Scholar
• Hak E, van Essen GA, Buskens E, Stalman W, de Melker RA. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands. J. Epidemiol. Community Health 52 (2), 120–125 (1998).
   Google Scholar
• White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics 103(6), e73 (1999).
   Google Scholar
• Bridges CB, Thompson WW Meltzer MI eta]. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAIVIA 284(13), 1655–1663 (2000).
   PubMed Web of Science ®Google Scholar
• Campbell DS, Rumley MET. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. I Occup. Envimn. Med. 39(5), 408–414 (1997).
   Google Scholar
• Kumpulainen V, Makela M. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J. Infect. Dis. 29(2), 181–185 (1997).
   Google Scholar
• Limcangco MR, Armour CL, Sable EG, Taylor SJ. Cost-benefit analysis of a kkemophilus influenzae type b meningitis prevention programme in The Philippines. PharmacoEconomics 19(4), 391–400 (2001).
   Google Scholar
• Miller MA. An assessment of the value of kkemophilus influenzae type b conjugate vaccine in Asia. Pecliab: Infect. Dis. J.17(9 Suppl.), S152-159 (1998).
   Google Scholar
• Garpenholt 0, Silfverdal SA, Levin LA. Economic evaluation of general childhood vaccination against kkemophilus billuenzae type b in Sweden. Scand J. Infect. Dis. 30(1), 5–10 (1998).
   Google Scholar
• Livartowski A, Boucher J, Detournay B, Reinert P. Cost-effectiveness evaluation of vaccination against kkemophilus billuenzae invasive diseases in France. Vaccine 14(6), 495–500 (1996).
   Google Scholar
• Pokorn M, Kopac S, Neubauer D, Cizman M. Economic evaluation of kkemophilus influenzae type b vaccination in Slovenia. Vaccine 19(25-26), 3600–3605 (2001).
   Google Scholar
• Jimenez FJ, Guallar-Castillon P, Rubio Terres C, Guallar E. Cost-benefit analysis of kkemophilus influenzae type b vaccination in children in Spain. PharmacoEconomics 15(1), 75–83 (1999).
   Google Scholar
• Edmunds WJ, Brisson M, Rose JD. The epidemiology of Herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19(23-24), 3076–3090 (2001).
   PubMed Web of Science ®Google Scholar
• Shadick NA, Liang MET, Phillips CB, Fossel K, Kuntz KM. The cost-effectiveness of vaccination against Lyme disease. Arch. Intern. Med. 161(4), 554–561 (2001).
   Google Scholar
• Meltzer MI, Dennis DT, Orloski IKA. The cost effectiveness of vaccinating against Lyme disease. Emerg. Infect. Dis. 5(3), 321–328 (1999).
   Google Scholar
• Gessner BD. The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly. Vaccine 18(15), 1485–1494 (2000).
   Google Scholar
• Rupnow MF, Owens DK, Shachter R, Parsonnet J. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology. Helicobacter 4(4), 272–280 (1999).
   PubMed Web of Science ®Google Scholar
• Carlin JB, Jackson T, Lane L, Bishop RF, Barnes GL. Cost effectiveness of rotavirus vaccination in Australia. Aust. NZJ Public Health 23(6), 611–616 (1999).
   Google Scholar
• Takala AK, Koskenniemi E, Joensuu J, Makela M, Vesikari T Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. Clin. Infect. Dir. 27(2), 272–282 (1998).
   Google Scholar
• Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAIVIA 279(17), 1371–1376 (1998).
   Web of Science ®Google Scholar
• Pelletier L, Chung P, Duclos P, Manga P, Scott J. A benefit-cost analysis of two-dose measles immunization in Canada. Vaccine 16(9-10), 989–996 (1998).
   PubMed Web of Science ®Google Scholar
• Zwanziger J, Szilagyi PG, Kaul P Evaluating the benefits of increasing measles immunization rates. Health Set-v. Res. 36(5), 885–909 (2001).
   Google Scholar
• Shiell A, Jorm LR, Carruthers R, Fitzsimmons GJ. Cost-effectiveness of measles outbreak intervention strategies. Aust. NZJ Public Health 22 (1), 126–132 (1998).
   PubMedGoogle Scholar
• Nettleman MD, Geerdes H, Roy MC. The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine. Arch. Intern. Med 157(10), 1121–1127 (1997).
   Google Scholar
• Ekwueme DU, Strebel PM, Hadler SC, Meltzer MI, Allen RV, Livengood JR. Economic evaluation of use of diphtheria, tetanus and acellular pertussis vaccine or diphtheria, tetanus and whole-cell pertussis vaccine in the United States, 1997. Arch. Pediatr Adolesc Med 154(8), 797–798 (2000).
   Google Scholar
• Berdeaux G, Lafuma A, Perruchet AM, Fagnani E Cost effectiveness of immunoprophylaxis in the prevention of recurrent infectious rhinitis in adults. PhalmacoEconomics 14 (3), 313–322 (1998).
   Google Scholar
• Graves PM. Comparison of the cost-effectiveness of vaccines and insecticide impregnation of mosquito nets for the prevention of malaria Ann. Trop. Med Patasitol 92(4), 399–410 (1998).
   Google Scholar
• Hyer RN, Howell MR, Ryan MA, Gaydos JC. Cost-effectiveness analysis of reacquiring and using adenovirus types 4 and 7 vaccines in naval recruits. Am. J. Tmp. Med Hyg 62(5), 613–618 (2000).
   Google Scholar
• Howell MR, Nang RN, Gaydos CA, Gaydos JC. Prevention of adenoviral acute respiratory disease in Army recruits: cost-effectiveness of a military vaccination policy. Am. Bev. Med 14(3), 168–175 (1998).
   Google Scholar
• Nancy A, Rao MR, Paquet C, Antona D, Sorkin A, Clemens JD. Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings: a cost-effectiveness analysis. JAIVIA 279(7), 521–525 (1998).
   Google Scholar
• Cookson ST, Stamboulian D, Demonte J et al A cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high-risk population. Int. Epidemiol 26(1), 212–219 (1997).
   Google Scholar
• Murray J, McFarland DA, Waldman RJ. Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera. Bull. World Health Chgan. 76(4), 343–352 (1998).
   Google Scholar
• Siraprapasiri T, Sawaddiwudhipong W, Rojanasuphot S. Cost benefit analysis of Japanese encephalitis vaccination program in Thailand. SoutheastAsianj 7i-op. Med Public Health 28(1), 143–148 (1997).
   Google Scholar
• Warren TA, Finder SF, Brier KL eta]. A cost-effectiveness analysis of typhoid fever vaccines in US military personnel. PharmacoEconomics 10(5), 475–483 (1996).
   Google Scholar
• Miller MA, Sutter RVV, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAIVIA 276(12), 967–971 (1996).
   PubMed Web of Science ®Google Scholar
• Bart KJ, Foulds J, Patriarca P. Global eradication of poliomyelitis: benefit-cost analysis. Bull World Health Chan. 74(1), 35–45 (1996).
   PubMed Web of Science ®Google Scholar
• Tucker AW, Isaacs D, Burgess M. Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia. Aust. NZ Public Health 25(5), 411–416 (2001).
   Google Scholar
• Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae type b and prospects for Streptococcus pneumoniae. Emerg. Inf. Dis. 5,336–345 (1999).
   PubMed Web of Science ®Google Scholar